Cumulatively, the results suggest that CD5L can be used as a lung cancer-specific EV biomarker for liquid biopsy because its expression is linked to cancer origin, and it represents a core regulatory molecule with respect to functions associated with lung cancer. Here, CD5L is linked to lung cancer.